131 related articles for article (PubMed ID: 11077963)
1. Preparation of (188Re) Re-AEDP and its biodistribution studies.
Qingnuan L; Xiaodong Z; Rong S; Wenxin L
Appl Radiat Isot; 2000 Dec; 53(6):993-7. PubMed ID: 11077963
[TBL] [Abstract][Full Text] [Related]
2. Labelling of Re-ABP with 188Re for bone pain palliation.
Arteaga de Murphy C; Ferro-Flores G; Pedraza-López M; Meléndez-Alafort L; Croft BY; Ramírez FM; Padilla J
Appl Radiat Isot; 2001 Mar; 54(3):435-42. PubMed ID: 11214878
[TBL] [Abstract][Full Text] [Related]
3. Endovascular beta irradiation for prevention of restenosis using solution radioisotopes: pharmacologic and dosimetric properties of rhenium-188 compounds.
Knapp FF; Guhlke S; Beets AL; Lin WY; Stabin M; Amols H; Weinberger J
Cardiovasc Radiat Med; 1999; 1(1):86-97. PubMed ID: 11272362
[TBL] [Abstract][Full Text] [Related]
4. 188Re-ethylene dicysteine: a novel agent for possible use in endovascular radiation therapy.
Das T; Banerjee S; Samuel G; Sarma HD; Ramamoorthy N; Pillai MR
Nucl Med Commun; 2000 Oct; 21(10):939-45. PubMed ID: 11130335
[TBL] [Abstract][Full Text] [Related]
5. Pentavalent rhenium-188 dimercaptosuccinic acid for targeted radiotherapy: synthesis and preliminary animal and human studies.
Blower PJ; Lam AS; O'Doherty MJ; Kettle AG; Coakley AJ; Knapp FF
Eur J Nucl Med; 1998 Jun; 25(6):613-21. PubMed ID: 9618576
[TBL] [Abstract][Full Text] [Related]
6. Preparation and biological evaluation of 188Re-ethylenediamine-N,N,N',N'-tetrakis(methylene phosphonic acid) as a potential agent for bone pain palliation.
Oh SJ; Won KS; Moon DH; Cheon JH; Ha HJ; Jeong JM; Lee HK
Nucl Med Commun; 2002 Jan; 23(1):75-81. PubMed ID: 11748441
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of carrier added and no carrier added 90Y-EDTMP as bone seeking therapeutic radiopharmaceutical.
Khalid M; Bokhari TH; Ahmad M; Bhatti HN; Iqbal M; Ghaffar A; Qadir MI
Pak J Pharm Sci; 2014 Jul; 27(4):813-8. PubMed ID: 25015445
[TBL] [Abstract][Full Text] [Related]
8. 188Re-labeled bisphosphonates as potential bifunctional agents for therapy in patients with bone metastases.
El-Mabhouh A; Mercer JR
Appl Radiat Isot; 2005 Apr; 62(4):541-9. PubMed ID: 15701408
[TBL] [Abstract][Full Text] [Related]
9. 188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases.
El-Mabhouh AA; Mercer JR
Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1240-8. PubMed ID: 18265977
[TBL] [Abstract][Full Text] [Related]
10. Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases.
Lin WY; Lin CP; Yeh SJ; Hsieh BT; Tsai ZT; Ting G; Yen TC; Wang SJ; Knapp FF; Stabin MG
Eur J Nucl Med; 1997 Jun; 24(6):590-5. PubMed ID: 9169563
[TBL] [Abstract][Full Text] [Related]
11. Labeling and quality control of 188Re-lanreotide.
Verdera S; Balter H; Rodríguez G; Oliver P; Souto B; López A; Goncalvez Z
Cell Mol Biol (Noisy-le-grand); 2002 Nov; 48(7):741-5. PubMed ID: 12619968
[TBL] [Abstract][Full Text] [Related]
12. Radiolabelling morpholinos with 188Re tricarbonyl provides improved in vitro and in vivo stability to re-oxidation.
He J; Liu C; Vanderheyden JL; Liu G; Dou S; Rusckowski M; Hnatowich DJ
Nucl Med Commun; 2004 Jul; 25(7):731-6. PubMed ID: 15208502
[TBL] [Abstract][Full Text] [Related]
13. 188Re(CO)3-dipicolylamine-alendronate: a new bisphosphonate conjugate for the radiotherapy of bone metastases.
Torres Martin de Rosales R; Finucane C; Foster J; Mather SJ; Blower PJ
Bioconjug Chem; 2010 May; 21(5):811-5. PubMed ID: 20387897
[TBL] [Abstract][Full Text] [Related]
14. 188Re(V)-DMSA revisited: preparation and biodistribution of a potential radiotherapeutic agent with low kidney uptake.
Dadachova E; Chapman J
Nucl Med Commun; 1998 Feb; 19(2):173-81. PubMed ID: 9548202
[TBL] [Abstract][Full Text] [Related]
15. Comparison of various rhenium-188-labeled diphosphonates for the treatment of bone metastases.
Hsieh BT; Hsieh JF; Tsai SC; Lin WY; Wang SJ; Ting G
Nucl Med Biol; 1999 Nov; 26(8):973-6. PubMed ID: 10708313
[TBL] [Abstract][Full Text] [Related]
16. Clinical applications of 188Re-labelled radiopharmaceuticals for radionuclide therapy.
Lambert B; de Klerk JM
Nucl Med Commun; 2006 Mar; 27(3):223-9. PubMed ID: 16479241
[TBL] [Abstract][Full Text] [Related]
17. Preparation and evaluation of rhenium-188-pamidronate as a palliative treatment in bone metastasis.
Erfani M; Rahmani N; Doroudi A; Shafiei M
Nucl Med Biol; 2017 Jun; 49():1-7. PubMed ID: 28279906
[TBL] [Abstract][Full Text] [Related]
18. Preparation of cyclotron-produced 186Re and comparison with reactor-produced 186Re and generator-produced 188Re for the labeling of bombesin.
Moustapha ME; Ehrhardt GJ; Smith CJ; Szajek LP; Eckelman WC; Jurisson SS
Nucl Med Biol; 2006 Jan; 33(1):81-9. PubMed ID: 16459262
[TBL] [Abstract][Full Text] [Related]
19. Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment.
Knapp FF; Beets AL; Guhlke S; Zamora PO; Bender H; Palmedo H; Biersack HJ
Anticancer Res; 1997; 17(3B):1783-95. PubMed ID: 9179235
[TBL] [Abstract][Full Text] [Related]
20. Preparation of rhenium-188-tin colloid as a radiation synovectomy agent and comparison with rhenium-188-sulfur colloid.
Jeong JM; Lee YJ; Kim YJ; Chang YS; Lee DS; Chung JK; Song YW; Lee MC
Appl Radiat Isot; 2000 Apr; 52(4):851-5. PubMed ID: 10800721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
